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Clinical studies suggest that the oral acyclic retinoid Peretinoin may reduce the recurrence of hepatocellular
carcinoma (HCC) following surgical ablation of primary tumours. Since hepatitis C virus (HCV) infection is
a major cause of HCC, we assessed whether Peretinoin and other retinoids have any effect on HCV infection.
For this purpose, we measured the effects of several retinoids on the replication of genotype 1a, 1b, and 2a
HCV in vitro. Peretinoin inhibited RNA replication for all genotypes and showed the strongest antiviral
effect among the retinoids tested. Furthermore, it reduced infectious virus release by 80–90% without
affecting virus assembly. These effects could be due to reduced signalling from lipid droplets, triglyceride
abundance, and the expression of mature sterol regulatory element-binding protein 1c and fatty acid
synthase. These negative effects of Peretinoin on HCV infection may be beneficial in addition to its potential
for HCC chemoprevention in HCV-infected patients.
H
epatitis C virus (HCV) is a causative agent of chronic hepatitis, liver cirrhosis, and hepatocellular carcin-
oma (HCC); therefore, the eradication of HCV from an infected liver could reduce death from HCV-
related liver disease. Combination therapy of PEGylated-interferon (PEG-IFN) and ribavirin has long
been the standard of care for patients with chronic hepatitis C (CH-C); however, a sustained viral response (SVR)
is obtained in only ,50% of treated patients infected with genotype 1 HCV1. Recently, several classes of direct-
acting antiviral agents (DAAs) have entered into clinical use. In the United States, two NS3/4A protease inhi-
bitors, telaprevir and boceprevir, were approved for use in combination with PEG-IFN and ribavirin in 2011.
Although the addition of these DAAs dramatically improves the SVR rate, 20–30% of patients still fail to eradicate
HCV due to breakthrough by drug-resistant mutants or null response to therapy2. More potent DAAs are
currently in late clinical development and promise much higher SVR rates even in the absence of PEG-IFN
therapy; however, HCV-related HCC is likely to continue to be a significant clinical issue for many years because
it will take time for potent DAAs to be distributed worldwide.
Peretinoin (generic name code: NIK-333) is an oral acyclic retinoid with a vitamin A-like structure that targets
retinoid nuclear receptors, such as retinoid X receptor and retinoic acid receptor. The oral administration of
Peretinoin significantly reduces the incidence of post-therapeutic HCC recurrence and improves the survival rate
of patients in clinical trials3,4. In addition, Peretinoin prevents the development of hepatoma in several different
hepatoma models5,6. Larger-scale clinical studies are currently ongoing in various countries to confirm its clinical
efficiency. Depending on the results of these studies, Peretinoin may be used in CH-C patients to prevent HCC.
Therefore, we sought to understand the effect of Peretinoin on HCV replication.
Peretinoin is categorised as a vitamin A or retinoid compound, and conflicting reports have described the
effects of vitamin A compounds on HCV replication. One report showed that 3 retinoids, 9-cis retinoic acid (RA),
13-cis RA, and all-trans RA (ATRA), suppressed the replication of a sub-genomic HCV replicon7. However,
vitamin A also reportedly enhances the replication of genome-length HCV in Huh-7 cells8. Here, we describe the
impact of Peretinoin on different steps of the HCV life cycle, including translation, RNA amplification, virus
assembly, and secretion, and its impact on host lipid metabolism in vitro. Our results clearly demonstrate that
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Results
Inhibition of HCV RNA replication by retinoids. Several studies
have tested the effects of vitamin A on HCV replication; these studies
used a sub-genomic or full-genomic replicon, which contains 2
cistrons, one driven by HCV internal ribosome entry sites (IRES)
and the other by encephalomyocarditis virus IRES7,8. We reported
the usefulness of HCV genomes containing Gaussia princeps
luciferase (GLuc) between p7 and NS2, followed by foot-and-
mouth disease virus 2A, to monitor HCV RNA replication9,10, and
this system is closer to physiological HCV replication than the
bicistronic replicon systems (Fig. 1A). In addition to GLuc-
containing HCV genomes in the backbone of genotype 1a H77S.3,
a chimeric clone of H77S and genotype 2a JFH1, HJ3-511, with
structural proteins from H77S and non-structural proteins from
JFH1, we also constructed GLuc-containing genomes in the
backbone of genotype 1b N12 and 2a JFH113 and confirmed their
efficient replication in Huh-7.5 cells. Importantly, all of the strains
used here are derived from cDNA clones that are infectious to
chimpanzees.
We initially examined the effects of 4 different retinoids, namely
ATRA, 9-cis RA, 13-cis RA, and Peretinoin, on HCV replication by
using these 4 HCV genomes containing GLuc, according to the use of
GLuc activity as an indicator of RNA replication, and the structures
of each retinoid were shown in Supplementary Fig. S1 online.
Peretinoin inhibited the replication of H77S.3/GLuc2A in a dose-
dependent manner (Fig. 1B). As the other retinoids also suppressed
HCV replication, we determined the antiviral half maximal effective
concentrations (EC50s) of these retinoids for each HCV genotype.
Whilst Peretinoin showed the strongest antiviral effect on all geno-
types tested, ATRA exerted a moderate effect, and 9-cis and 13-cis
RA generated a weaker effect (Table 1). Especially, Peretinoin sup-
pressed the RNA replication of H77S.3/GLuc2A most efficiently and
its EC50 was 9 mM.
We also determined the half maximal cytotoxicity concentrations
(CC50s) of these retinoids in H77S.3/GLuc2A-replicating Huh-7.5
cells by using the WST-8 assay, which reflects cell number. The
CC50s of ATRA, 9-cis RA, and 13-cis RA were more than 100 mM;
however, the CC50 of Peretinoin was 68 mM when the cells were
treated for 72 h (Table 2). Although Peretinoin had a slightly nega-
tive impact on cell growth, as it showed the strongest antiviral effect
and may be used for HCC chemoprevention in HCV-infected
patients in the future, we focused upon the action of Peretinoin
among these retinoids.
Inhibition of HCV RNA replication by Peretinoin. We examined
the time dependence of the antiviral effect of Peretinoin. After HCV
RNA transfection, we treated the transfected cells with Peretinoin at
a range of concentrations (10–40 mM) and monitored RNA
replication every 24 h until 72 h. Peretinoin started to show an
antiviral effect from 24 h after treatment, which continued until
72 h. Peretinoin suppressed RNA replication in a time-dependent
manner for all genotypes tested (Fig. 1C).
We also examined whether Peretinoin could also suppress RNA
replication in a sub-genomic replicon system (Fig. 1D), in which
infection should not occur due to the lack of structural proteins.
Peretinoin was also able to suppress RNA replication in a dose-
dependent manner in bicistronic sub-genomic RNA-transfected
cells (Fig. 1E).
Importantly, when we treated HCV (H77S.3/GLuc2A)-replicating
and HCV-non-replicating Huh-7.5 cells with Peretinoin at a range of
concentrations (5–50 mM), the cell numbers were identical under the
conditions tested (Fig. 1F).
As Peretinoin could suppress GLuc activity itself, we then exam-
ined directly its antiviral effect in the context of an HCV genome
lacking the GLuc genome. For this purpose, Huh-7.5 cells infected
with cell culture-derived HCV (HCVcc) of HJ3-5 were treated with
different concentrations of Peretinoin. When we monitored HCV
RNA replication by using quantitative real-time detection-polymer-
ase chain reaction (RTD-PCR) (Fig. 2A) and protein expression by
western blotting for the HCV core protein (Fig. 2B, see Supple-
mentary Fig. S2 online), Peretinoin suppressed RNA replication
and protein expression in a dose-dependent manner, which is con-
sistent with the GLuc activity results. We also tested infectious virus
production from Peretinoin-treated cells using a conventional focus
forming unit (FFU) assay, and found that Peretinoin also reduced
this in a dose-dependent manner (Fig. 2C).
Effect of Peretinoin on translation driven by HCV IRES. We also
tested the effect of Peretinoin on translation directed by HCV IRES.
For this purpose, we used a mini-genome RNA which has,
sequentially, the HCV 59-untranslated region (UTR), GLuc, and
HCV 39-UTR, and cap-Cypridina luciferase (CLuc)-polyA RNA as
a control (see Supplementary Fig. S1 online). After we treated Huh-
7.5 cells with different concentrations of Peretinoin for 24 h, we co-
transfected the cells with these RNAs and measured GLuc and CLuc
activity every 3 h from 3 to 12 h. When we normalised GLuc activity
to CLuc activity at each time point, we did not observe a significant
difference among the cells treated with the different concentrations
of Peretinoin (see Supplementary Fig. S3 online), suggesting that
Peretinoin does not have an effect on protein expression directed
by HCV IRES.
Effect of Peretinoin on cellular interferon signalling. We hypothe-
sised that the suppression of RNA replication by Peretinoin could be
due to the activation or enhancement of cellular interferon (IFN)
signalling. To examine this, we treated HCV (H77S.3/GLuc2A)-non-
replicating and HCV-replicating Huh-7.5 cells with either IFNa-2b
(10 IU/mL) or Peretinoin (10–40 mM) and monitored the expres-
sion of total and phosphorylated signal transducer and activator of
transcription 1 (STAT1). Peretinoin did not alter the expression of
either total or phosphorylated STAT1 in HCV-non-replicating Huh-
7.5 cells or HCV-replicating cells (see Supplementary Fig. S4 online).
In addition, Peretinoin did not further enhance the amount of phos-
phorylated STAT1 activated by IFNa-2b in HCV-non-replicating
Huh-7.5 cells or HCV-replicating cells (see Supplementary Fig. S4
online). These data suggest that Peretinoin suppresses RNA
replication without either activating or enhancing cellular IFN
signalling.
Impact of Peretinoin on lipid metabolism. As lipid metabolism has
an important role in various aspects of HCV infection14–16, we
examined the impact of Peretinoin on lipid metabolism. However,
as it is sometimes difficult to detect small changes in lipid
metabolism, we tested the effect of Peretinoin under oleic acid
(OA) treatment, which amplifies changes in lipid metabolism. We
treated H77S.3/GLuc2A-replicating Huh-7.5 cells with 40 mM
Peretinoin and 250 mM OA, fixed and stained the cells with
BODIPY 493/503 for lipid droplets (LDs) and 49, 6-diamidino-2-
phenylindole (DAPI) for nuclei, and used an anti-core protein
antibody to detect HCV. When we stained LDs in the presence of
250 mM OA and the absence of Peretinoin, we observed intense
signals (Fig. 3A); however, when it was accompanied with 40 mM
Peretinoin, the signals from LDs were dramatically reduced, and at
the same time, the expression of HCV core protein was also down-
regulated (Fig. 3B). When we quantitated the signal strength from
LDs and HCV core protein in 4 different fields, Peretinoin
significantly reduced the signals from LDs and HCV core protein
(two-tailed Student’s t test, p,0.0001 for each) (Fig. 3C). This
reduction was also confirmed by the quantitation of the 5 cells
which were positive for both LDs and HCV core (see
Supplementary Fig. S5 online). The reduced expression of HCV
core protein was also observed by western blot analysis (Fig. 3D,
see Supplementary Fig. S6 online). We next investigated the
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Figure 1 | Antiviral effects of several retinoids and their effects on cell growth. (A) Schematic representation of the GLuc-containing HCV genome. (B)
Huh-7.5 cells were transfected with H77S.3/GLuc2A RNA, and 48 h later, 0.5% DMSO or Peretinoin was added at concentrations ranging from 1 to
100 mM. Fresh medium containing Peretinoin was added every 24 h, and 72 h after adding Peretinoin, secreted GLuc activity was measured. The GLuc
activity from Peretinoin-treated cells was normalised to that with DMSO treatment. Data show the mean inhibition to DMSO treatment in each
concentration of Peretinoin 6 SD from 3 independent experiments. (C) Huh-7.5 cells were transfected with H77S.3/GLuc2A, N.2/GLuc2A, HJ3-5/
GLuc2A, and JFH1/GLuc2A RNAs, and 48 h later, 0.5% DMSO or Peretinoin was added at the indicated concentrations. The medium was collected and
replaced with fresh medium every 24 h until 72 h. GLuc activity was determined at each time point. The results shown represent the mean GLuc activity 6
SD from 3 different plates. (D) Schematic representation of the bicistronic sub-genomic HCV RNA (E) Huh-7.5 cells were transfected with bicistronic
sub-genomic RNA. At 48 h later, the transfected cells were treated with the indicated concentrations of Peretinoin for 72 h. Quantification of HCV RNA
and 18S rRNA levels was performed and relative HCV RNA abundance normalised to the amount of 18S rRNA is presented as fold change 6 SD
compared to DMSO-treated cells from 3 independent experiments. (F) Huh-7.5 cells were transfected with H77S.3/GLuc2A RNA, and 7 days later, HCV
(H77S.3/GLuc2A)-replicating Huh-7.5 cells, depicted as ‘HCV1’, were treated with the indicated concentrations of Peretinoin and HCV-non-replicating
Huh-7.5 cells, depicted as ‘HCV-’, were also treated in a same way. At 72 h after Peretinoin treatment, cell numbers were determined by using a Cell
Counting Kit-8. Data represent relative cell numbers 6 SD from 3 independent experiments to DMSO-treated cells. EMCV, Encephalomyocarditis virus;
NeoR, Neomycin resistance gene; NT, no treatment.
www.nature.com/scientificreports
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impact of Peretinoin on lipid metabolism by measuring intracellular
triglyceride (TG) levels, which should mainly reflect the amount of
LDs, following treatment with 0–40 mM Peretinoin with or without
HCV replication and OA treatment. Peretinoin reduced intracellular
TG levels in a dose-dependent manner, regardless of OA treatment
and HCV replication (Fig. 4A). These effects may be primarily due to
its transcriptional modulation. To address this possibility, we
examined the effect of Peretinoin on the transcription of fatty acid
synthase (FASN) using RTD-PCR under 0–40 mM Peretinoin with
or without HCV replication and OA treatment, because FASN is a
key enzyme for the synthesis of fatty acids, which are an essential
component of TGs. Peretinoin reduced the mRNA levels of FASN in
a dose-dependent manner, regardless of OA treatment and HCV
replication (Fig. 4B). We also examined FASN protein expression
as well as the levels of precursor and mature sterol regulatory
element-binding protein 1c (SREBP1c), which is a critical
transcription factor for FASN. Peretinoin reduced the expression
of FASN protein, which is consistent with the RTD-PCR results
(Fig. 4C, see Supplementary Fig. S7 online). Although Peretinoin
did not have an effect on precursor SREBP1c protein expression, it
dramatically reduced the levels of mature SREBP1c (Fig. 4C, see
Supplementary Fig. S7 online). We also observed a reduction of
FASN mRNA levels by Peretinoin in an immortalised human
hepatocyte cell line (Fig. 5A), and a similar reduction was also
observed for ATRA, 9-cis RA, and 13-cis RA treatment of HCV-
replicating Huh-7.5 cells (Fig. 5B). These results indicate that
Peretinoin reduced intracellular lipid levels by reducing the
amount of mature SREBP1c and, subsequently, FASN.
Specific inhibition of virus secretion by Peretinoin. Recently, lipids
including LDs and TG have been reported to be important for
efficient infectious virus production14–16. Due to its huge impact on
lipid metabolism, Peretinoin could affect virus assembly or secretion
as well as RNA amplification. To test the effect of Peretinoin on
infectious virus production, we determined intra- and extra-
cellular infectivity and the virus secretion ratio by measuring the
amount of intra- and extra-cellular infectious virus from HJ3-5/
GLuc2A-replicating FT3-7 cells treated with various concentra-
tions of Peretinoin. We infected naı̈ve Huh-7.5 cells with intra-
and extra-cellular virus derived from HJ3-5/GLuc2A-replicating
cells after Peretinoin treatment and used GLuc activity as an
indicator of infectious virus production because FFUs and GLuc
activity were well correlated (see Supplementary Fig. S8 online),
and a previous report also showed a good correlation between
them17. Although Peretinoin did not show a significant impact on
intracellular infectivity at 10–30 mM, it dramatically reduced
extracellular infectivity and virus secretion from 10 mM when we
normalised intra- and extra-cellular infectivity by the replication
capacity of the virus producing the intra- and extra-cellular virus,
as determined by GLuc activity (Fig. 6A). This result was also
confirmed by using the extra-cellular virus which was prepared by
centrifugation and subsequently re-suspended to fresh medium
without containing Peretinoin, indicating that possible carryover
of Peretinoin in the medium from extra-cellular cultures does not
affect the result shown in Figure 6A (Supplementary Fig. S9 online).
Interestingly, the expression of apolipoprotein E3 (ApoE3), which is
essential for virus secretion, was also suppressed by Peretinoin
(Fig. 4C, see Supplementary Fig. S7 online). Furthermore, we
compared the buoyant density of HCVcc derived from HJ3-5/
GLuc2A-replicating FT3-7 cells by equilibrium gradient
ultracentrifugation. HCVcc from HJ3-5/GLuc2A-replicating cells
treated with dimethyl sulfoxide (DMSO) or 30 mM Peretinoin
showed exactly the same peak of infectivity at 1.107 g/cm3 (Fig. 6B,
6C). Specific infectivity, as calculated from both peaks of HCV RNA
and GLuc activity, was 0.0381 6 0.0209 (standard deviation, SD)
light units (LU)/copy for DMSO-treated cells, and 0.0799 6 0.0457
LU/copy for Peretinoin-treated cells, which did not show a
considerable difference. Furthermore, Peretinoin did not affect
virus entry of HCVcc when we tested it by RT-PCR for HCV RNA
at 5 h after infection and an FFU assay at 72 h after infection (see
Supplementary Fig. S10 online). Collectively, Peretinoin seems to
inhibit virus release in addition to viral RNA amplification.
Discussion
In the present study, we clearly showed that Peretinoin, as well as
ATRA, 9-cis RA, and 13-cis RA, suppressed HCV RNA replication
(Table 1). While previous reports used replicon systems to test the
effects of retinoids, we used a genome-length HCV containing a
GLuc-coding sequence between p7 and NS2, which is more physio-
logical than replicons. The inhibitory effect of retinoids was universal
among the HCV genotypes tested, and all retinoids tested showed an
inhibitory effect on HCV replication (Table 1). In addition, we also
observed the antiviral effect of Peretinoin in the replicon system
(Fig. 1E). Therefore, our present data strongly support the notion
that retinoids exert an antiviral effect in vitro. The antiviral effect of
retinoids has also been confirmed in a clinical study. Even when CH-
C patients were treated with ATRA, the viral load dropped by 1–2 log
units in 50% of the patients enrolled. In addition, when CH-C
patients who showed no response to prior IFN/PEG-IFNa and riba-
virin therapy were treated with a combination of ATRA and PEG-
IFNa-2a, 30% of patients showed a significant viral reduction18.
Recently, combined vitamin A and D deficiency prior to IFN-based
therapy was shown to be a strong independent predictor of non-
response to antiviral therapy19. Collectively, our data and the clinical
findings indicate that retinoids possess inhibitory effects on HCV
replication.
Peretinoin showed the strongest antiviral effect among the reti-
noids tested (Table 1); thus, we focused on Peretinoin to clarify its
antiviral mechanism. A previous report showed that 9-cis RA
enhanced the antiviral effect of IFNa by increasing the expression
of the IFNa receptor20; however, another study showed that ATRA
did not induce the activation of dsRNA-activated protein kinase R,
which is a key player in the IFN-induced antiviral response7. In the
present study, Peretinoin did not increase the amount of the acti-
vated form of STAT-1, which is pSTAT1, contrary to IFNa-2b, both
in HCV-replicating and HCV-non replicating Huh-7.5 cells, and
dual treatment of Huh-7.5 cells with IFNa-2b and Peretinoin did
not show a further increase of the pSTAT1 levels induced by only
IFNa-2b (see Supplementary Fig. S4 online), indicating that
Table 1 | EC50 of vitamin A compounds on HCV RNA replication
Peretinoin ATRA 9-cis RA 13-cis RA
Mean SD Mean SD Mean SD Mean SD
HCV (mM) (mM) (mM) (mM) (mM) (mM) (mM) (mM)
H77S.3 9 1 32 3 29 7 41 4
N.2 19 1 53 5 75 8 83 17
HJ3-5 18 2 25 1 51 6 82 17
JFH1 20 1 25 1 61 8 78 11
Table 2 | CC50 of vitamin A compounds on Huh-7.5 cells support-
ing HCV replication
Peretinoin ATRA 9-cis RA 13-cis RA
Mean SD Mean Mean Mean
(mM) (mM) (mM) (mM) (mM)
68 5.2 .100 .100 .100
www.nature.com/scientificreports
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Peretinoin did not activate or enhance cellular IFN signalling. Our
results also indicate that the antiviral effect of Peretinoin is not due to
the suppression of HCV translation directed by HCV IRES (see
Supplementary Fig. S3 online). As Peretinoin suppressed the RNA
replication of bicistronic sub-genomic replicons (Fig. 1E), it seems to
suppress RNA amplification itself (see also the later description of
FASN). A report showed that retinoids inhibited HCV RNA replica-
tion by enhancing the expression of gastrointestinal-glutathione per-
oxidase (GI-GPx) only in the presence of sodium selenite7; however,
in the present study, we demonstrated that all retinoids tested inhib-
ited HCV replication, even in the absence of sodium selenite. Thus,
our results support the notion that the observed antiviral effects
could be independent of GI-GPx, although supplementation with
sodium selenite may further enhance the antiviral effects of retinoids.
To clarify the mechanism underlying the antiviral effect of
Peretinoin further, we focused on the effect of Peretinoin on lipid
metabolism because it has been shown to modify multiple aspects of
HCV infection14–16, and we detected a significant reduction of FASN
Figure 2 | Inhibition of HCV replication and infectious virus production. Huh-7.5 cells were infected with the HJ3-5 virus at a multiplicity of infection
(MOI) of 1, and 72 h later, DMSO or Peretinoin was added at the indicated concentrations. The medium was replaced with fresh medium every 24 h until
72 h. (A) At 72 h after adding Peretinoin, total cellular RNA was extracted, and the amount of HCV RNA and 18S rRNA was quantitated by RTD-PCR.
Relative HCV RNA abundance normalised to the amount of 18S rRNA is presented as fold change 6 SD compared to DMSO-treated cells from 3
independent experiments. (B) At 72 h after Peretinoin treatment, the cell lysates were collected and subjected to western blot analysis using anti-core
protein and anti-b-actin antibodies. Full-length blots/gels are presented in Supplementary Fig. S2 online. (C) The medium was collected at 72 h after
Peretinoin treatment, and immediately, naı̈ve Huh-7.5 cells were infected with serially diluted medium. At 72 h after infection, the infectious virus titre of
HCVcc from Peretinoin-treated cells was determined by an FFU assay. Data shown here represent the mean FFUs/mL 6 SD from 2 independent
experiments.
www.nature.com/scientificreports
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mRNA levels by Peretinoin in a mouse hepatoma model, implying
its possible effect on lipid metabolism5. Surprisingly, Peretinoin
strongly reduced the signal from LDs in the presence of OA and
intracellular TGs (Fig. 3A–C, 4A). LDs are known to have an
essential role in the assembly of HCV virus particles by interacting
with HCV core protein and NS5A21,22. Therefore, we examined the
effect of Peretinoin on several steps of infectious virus production,
such as assembly and secretion. Interestingly, Peretinoin specifically
Figure 3 | Reduction of LD signals by Peretinoin. Huh-7.5 cells were infected with HJ3-5 virus at an MOI of 1, and 72 h later, 250 mM OA and DMSO or
250 mM OA and 40 mM Peretinoin were added, and the following assay was performed at 72 h later. (A, B) At 72 h later, the cells were fixed and stained
for nuclei, LDs, and HCV core protein. (A) Shows 250 mM OA and DMSO-treated cells and (B) shows 250 mM OA and 40 mM Peretinoin-treated cells.
The photos in (A) and (B) were taken under exactly the same conditions. (C) The signal intensity from LDs, HCV core protein, and nuclei was quantitated
as described in the Methods. Data shown represent mean signal intensity 6 SD from 4 different areas, and the difference was analysed statistically using
Student’s t-test. (D) Cell lysates were collected and subjected to western blot analysis using anti-core protein and anti-b-actin antibodies. Full-length
blots/gels are presented in Supplementary Fig. S6 online. N.S., not significant.
www.nature.com/scientificreports
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Figure 4 | Mechanism by which Peretinoin alters lipid metabolism. Huh-7.5 cells were transfected with H77S.3/GLuc2A RNA, and 72 h later, the
transfected cells, depicted as ‘HCV(1)’, and non-transfected Huh-7.5 cells, depicted as ‘HCV(-)’, were treated with or without 250 mM OA in the
presence of 2% fatty acid-free BSA with 0.5% DMSO or 10–40 mM Peretinoin, and the following assay was performed at 72 h later. (A) The concentration
of intracellular TGs was measured. Data shown represent mean concentration 6 SD from 3 independent experiments. (B) RNA was extracted and the
levels of FASN mRNA and 18S rRNA were quantitated by RTD-PCR. FASN levels were normalised to those of 18S rRNA, and the ratio was furthermore
normalised to that from DMSO-treated cells. The results presented here represent the relative fold of FASN/18S rRNA 6 SD from 3 independent
experiments at the indicated conditions. (C) Lysates from the cells without OA treatment were collected and subjected to western blot analysis using anti-
FASN, anti-precursor SREBP1c, anti-mature SREBP1c, anti-ApoE3, and anti-b-actin antibodies. Full-length blots/gels are presented in Supplementary
Fig. S7 online.
www.nature.com/scientificreports
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impaired virus secretion without affecting assembly at 10–30 mM,
whilst 40 mM Peretinoin impaired virus secretion and assembly
(Fig. 6A). The role of LDs in virus secretion has not been fully
characterised, but virus should be secreted through the production
and release of very low-density lipoproteins. In addition to micro-
somal triglyceride transfer protein and several apolipoproteins, such
as ApoB and ApoE23, small interfering RNA screening revealed that
multiple components of the secretary pathway, including endoplas-
mic reticulum to Golgi trafficking and lipid and protein kinases, are
involved in HCV secretion24. Thus, the mechanism underlying this
specific inhibition of virus secretion by Peretinoin remains to be
addressed. One possible explanation for its action is the reduction
of ApoE3 expression (Fig. 4C), because ApoE3 was shown to have an
important role in virus secretion with a minimal impact on
assembly25.
Several reports showed that LDs play an essential role in RNA
amplification and virus assembly. The hypolipidemic agent nordihy-
droguaiaretic acid reduced the number of LDs, resulting in the sup-
pression of RNA amplification and virus secretion, as Peretinoin
did26. Furthermore, inhibition of tail-interacting protein 47, which
coats LDs and is involved in their generation and turnover, sup-
pressed HCV RNA replication and assembly27,28. Thus, the inhibition
of RNA replication by Peretinoin could be explained by its direct
effect on LDs. In addition, a recent report suggested that FASN may
localise within HCV replication complexes through an interaction
with NS5B, thereby increasing its RNA-dependent RNA polymerase
activity29. Thus, Peretinoin may inhibit RNA replication not only by
reducing the signalling of LDs but also inhibiting the expression of
FASN.
We also demonstrated that Peretinoin reduced the levels of mature
SREBP1c by inhibiting the proteolysis of its precursor, and subse-
quently the transcription and expression of FASN (Fig. 4C), which
could be the main reason for the alteration of lipid metabolism by
Peretinoin; however, the mechanism by which it inhibits proteolysis
should be addressed in a future study. Several reports have shown
that the expression of SREBP1c and/or FASN is increased in HCV-
infected patients30, Huh-7 cells31, and a transgenic mouse expressing
the full-length HCV polyprotein32. In addition, HCV infection was
shown to enhance the proteolytic cleavage of precursor SREBP1c,
resulting in an increase in its mature form33. Taken together, HCV
induces lipogenesis to make infected cells more supportive for its
propagation. In contrast to HCV, Peretinoin seems to suppress lipo-
genesis by inhibiting the SREBP1c-FASN axis, which is highly acti-
vated by HCV infection. It is also important to note that this effect
did not depend on HCV infection, indicating that Peretinoin should
exert a hypolipidemic effect, as we also observed a reduction of FASN
mRNA levels following Peretinoin treatment of an immortalised
human hepatocyte cell line (Fig. 5A). Interestingly, this effect was
universal among retinoids because the other retinoids examined also
reduced FASN mRNA levels (Fig. 5B). These findings suggest that
Peretinoin could also be useful for the treatment of non-alcoholic
fatty liver disease, whose hallmark is hepatic fat accumulation.
The antiviral EC50 of Peretinoin seems to be closer to its CC50 than
that of the other retinoids in Huh-7.5 cells because several papers
have shown that Peretinoin inhibits the growth of hepatoma cells in
vivo and in vitro34,35, induces apoptosis in human hepatoma cell
lines36, and causes an arrest of the cell cycle in G0-G1 in human
hepatoma cell lines35, indicating that Peretinoin should selectively
Figure 5 | Reduction of FASN mRNA levels by Peretinoin in a human hepatocyte cell line and the effects of ATRA, 9-cis RA, and 13-cis RA on the
expression of FASN mRNA. (A) An immortalised human hepatocyte cell line, THLE-5b cells, was treated with the indicated concentrations of
Peretinoin. At 72 h later, RNA was extracted and reverse transcribed, and the levels of FASN mRNA and 18S rRNA were quantified by RTD-PCR. The
relative amount of FASN mRNA normalised to that of 18S rRNA is presented as fold change compared to DMSO-treated cells from 3 independent
experiments at the indicated conditions. (B) Huh-7.5 cells were transfected with H77S.3/GLuc2A RNA. At 72 h later, the transfected cells were treated
with DMSO or 10–40 mM ATRA, 9-cis RA, and 13-cis RA. At 72 h later, RNA was extracted and the levels of FASN mRNA and 18S rRNA were quantified
by RTD-PCR. The relative amount of FASN mRNA was determined as described in Fig. 4 and presented as fold change compared to DMSO-treated cells
from 3 independent experiments at the indicated conditions.
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Figure 6 | Impact of Peretinoin on infectious virus production. (A) FT3-7 cells were transfected with HJ3-5/GLuc2A RNA, and 7 days later, 0.5% DMSO,
or 10–40 mM Peretinoin, were added. At 72 h later, extra- and intra-cellular viruses were collected and used to infect naı̈ve Huh-7.5 cells. Replication
capacity was also determined by measuring secreted GLuc activity. At 48 h after infection, we determined the amount of infectious virus from extra- and
intra-cellular media by using GLuc activity as an indicator of the amount of infectious virus. Intra- and extra-cellular infectivity was normalised to
replication capacity at infection, and these were then normalised to those of DMSO-treated cells, which were set to 100%. The ratio of extracellular
infectious virus to intracellular virus was calculated at the indicated conditions, and it was then normalised to DMSO-treated cells, which were set to
100%. Data show the mean ratio to that of DMSO-treated cells 6 SD from 3 independent experiments. (B, C) FT3-7 cells were transfected with HJ3-5/
GLuc2A RNA, and 7 days later, 0.5% DMSO or 30 mM Peretinoin were added, and then 72 h later, the medium was collected and subjected to equilibrium
ultracentrifugation. Fourteen fractions were taken and analysed for density (circles), HCV RNA levels (diamonds), and infectious virus titres determined
by GLuc activity (grey bars). (B) shows the results from DMSO-treated cells, whilst (C) shows those for Peretinoin-treated cells.
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suppress the growth of hepatoma cells, although the mechanism has
not been fully understood. However, pharmacokinetic data from
humans showed that the mean plasma concentration of lipid-
bounded Peretinoin is 7.3 mM when patients received 600 mg
Peretinoin daily for 8 weeks37. This concentration is very close to
the antiviral EC50 and could have an inhibitory effect on HCV rep-
lication, indicating that we could expect an antiviral effect at this dose
in humans. Peretinoin showed an additive antiviral effect when com-
bined with IFNa-2b (data not shown); furthermore, HCV did not
acquire resistance to Peretinoin after 14 days treatment with 10–
40 mM Peretinoin (see Supplementary Fig. S11 online). Although it
could be difficult to eradicate HCV only by Peretinoin due to its low
selective index (CC50/EC50), combination therapy with Peretinoin
plus PEG-IFN, ribavirin, or DAAs may further improve the SVR rate,
as vitamin D has been proved to do38,39.
In summary, we have demonstrated that Peretinoin, which may in
the future be administered to patients infected with HCV to prevent
HCC, inhibits HCV RNA replication and infectious virus release by
modifying several aspects of lipid metabolism.
Methods
Cell lines. Huh-7.5 (kindly provided by Professor C. M. Rice, Rockefeller University,
New York, NY), and FT3-7 cells (both clonal derivatives of Huh-7 cells) were
maintained as described previously9. We used an immortalised human hepatocyte
cell line, THLE-5b cells40, for the indicated experiments.
Reagents. Peretinoin and IFNa-2b were kindly provided by KOWA Company, Ltd.
(Tokyo, Japan). ATRA, 9-cis RA, and 13-cis RA, were purchased from Sigma-Aldrich
Japan K.K. (Tokyo, Japan). Stock solutions were prepared in DMSO, and all final
dilutions contained 0.5% DMSO.
Plasmids. The GLuc coding sequence, followed by the FMDV2A sequence, was
inserted between p7 and NS2 in pJFH1 and pHCV-N.2, which encode cDNA of
genotype 2a JFH113 and genotype 1b N12, carrying several replication-enhancing
mutations to be described elsewhere, respectively, by the same strategy adopted
previously for H77S10. pH77S.3/GLuc2A10, pHJ3-5/GLuc2A9, and pHJ3-511 have been
described previously.
Antiviral activity assay. The indicated HCV RNAs were transfected by
electroporation. The medium was replaced with fresh medium containing serial
dilutions of the antiviral compounds at 48 h, and at 24 h intervals thereafter. Secreted
GLuc activity was determined at 72 h after adding the antiviral compounds. The
concentration of each compound required to reduce the amount of secreted GLuc
activity by 50% (EC50) was determined using a 3-parameter Hill equation (Sigma Plot
10.0).
Cell number determination. Huh-7.5 cells were seeded in 96-well plates at a density
of 5,000 cells/well, and at 24 h later, the indicated compounds were added. Cell
numbers were determined by a WST-8 assay using Cell Counting Kit-8. The
concentration of each compound required to reduce the amount of cell number by
50% (CC50) was determined using a 3-parameter Hill equation (Sigma Plot 10.0).
RNA transcription. HCV RNAs were synthesised using a MEGAscript T7 Kit, and
synthesised RNA was purified using an RNeasy Mini Kit.
Virus yield determination. Huh-7.5 cells were seeded in 48-well plates at a density of
4.0 3 104 cells/well at 24 h prior to inoculation with 100 mL of virus-containing
medium. The cells were maintained at 37uC in a 5% CO2 environment and fed with
300 mL medium at 24 h later. Following 48 h of additional incubation, the cells were
fixed in methanol-acetone (151) at room temperature for 9 min and stained with a
C7-50 monoclonal antibody to the HCV core protein (15300). After extensive
washing, the cells were stained with Alexa Fluor 568-conjugated anti-mouse IgG
antibodies. A cluster of infected cells staining for core antigen was considered to
constitute a single infectious FFU; virus titres are reported as FFUs/mL.
Western blotting and immunostaining. Western blotting and immunostaining
were performed as described previously41,42. Briefly, the cells were washed in
phosphate-buffered saline (PBS) and lysed in a radioimmunoprecipitation assay
buffer containing complete Protease Inhibitor Cocktail and PhosSTOP. The
membranes were blocked in Blocking One or Blocking One-P solution, and the
expression of HCV core protein, FASN, precursor and mature SREBP1c, ApoE3, and
b-actin was evaluated with mouse anti-core protein, rabbit anti-FASN, rabbit anti-
SREBP1c, goat anti-ApoE3, and rabbit anti-b-actin antibodies, respectively.
For immunofluorescence staining, the cells were washed twice with PBS and fixed
in 4% paraformaldehyde for 15 min at room temperature. After washing again with
PBS, the cells were permeabilised with 0.05% Triton X-100 in PBS for 15 min at room
temperature. They were incubated in a blocking solution (10% foetal bovine serum
and 5% bovine serum albumin [BSA] in PBS) for 30 min, and then with the anti-core
protein monoclonal antibodies. The fluorescent secondary antibodies were Alexa
Fluor 568-conjugated anti-mouse IgG antibodies. Nuclei were labelled with DAPI,
and LDs were visualised with BODIPY 493/503. Imaging was performed on a
BIOREVO fluorescence microscope (Keyence Corporation, Osaka, Japan). The signal
strength of LDs, core protein, and nuclei was quantitated by using Measurement
Module BZ-H1M (Keyence Corporation).
Quantitative RTD-PCR. The primer pairs and probes for FASN and 18S rRNA were
obtained from the TaqMan assay reagents library. HCV RNA was detected as
described previously43.
Secreted luciferase assay. Cell culture supernatant fluids were collected at intervals
after RNA transfection and the cells were re-fed fresh medium. Secreted GLuc was
measured as described previously9.
Fatty acid treatment and measurement of TGs. The cells were treated with the
indicated concentrations of OA in the presence of 2% fatty acid-free BSA.
Intracellular TG content was measured using a TG Test according to the
manufacturer’s instructions.
Intra- and extra-cellular infectivity assay. To determine the amount of intra-cellular
infectious virus, cell pellets of HJ3-5/GLuc2A-replicating FT3-7 cells harvested after
trypsinization were resuspended in complete medium, washed twice with PBS, and
lysed by 4 cycles of freezing and thawing. The lysates were clarified by centrifugation
at 2,300 3 g for 5 min prior to inoculation onto naı̈ve Huh-7.5 cells. At the same time,
extra-cellular medium was also collected. The medium derived from extra- and intra-
cellular cultures was used to infect naı̈ve Huh-7.5 cells, which were plated in 48-well
plates at a density of 4.0 3 104 cells/well at 24 h prior to infection. After 6 h
inoculation, medium containing virus and possible carryover of Peretinoin was
removed by extensive wash, and medium was replaced with fresh one every 24 h until
48 h. At 48 h after infection, we determined GLuc activity and used it as an indicator
of the infectious virus titre.
Equilibrium ultracentrifugation of HJ3-5/GLuc2A virus particles using an
isopycnic iodixanol gradient. Filtered supernatant fluids collected from HJ3-5/
GLuc2A virus-replicating FT3-7 cells treated with DMSO or 30 mM Peretinoin for
72 h were concentrated 30-fold using a Centricon PBHK Centrifugal Plus-20 Filter
Unit with an Ultracel-PL membrane (100-kDa exclusion; Merck Millipore, Billerica,
MA), then layered on top of a preformed continuous 10–40% iodixanol gradient in
Hanks’ balanced salt solution. The gradients were centrifuged in an SW41 rotor at
209,678 3 g for 16 h at 4uC, and fractions (500 mL each) were collected from the top
of the tube. The density of each fraction was determined using a digital refractometer.
Virus RNA was isolated from each gradient fraction using a QIAamp Viral RNA Kit,
and cDNA was synthesised using a High Capacity cDNA Reverse Transcription Kit.
RTD-PCR to quantitate the amount of HCV RNA was performed using a 7500 Real
Time PCR System. Each fraction was used to infect naı̈ve Huh-7.5 cells for 6 h,
followed by extensive washing to ensure GLuc activity was reduced to background.
The infected cells were inoculated and the medium was replaced with fresh medium
every 24 h. GLuc activity, which was used an alternative to the infectious virus titre,
was determined at 72 h after infection.
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